The Group aims to enhance its corporate value into the future and promotes its business activities in line with the “NOF VISION 2030,” its strategic policy. In the first half of the current fiscal year, which is the middle phase of the 2025 Mid-Term Management Plan, a stage positioned for expanding profit, although demand for raw materials for DDS drug formulations in the Pharmaceuticals, Medicals and Health Segment temporarily stalled, the Functional Chemicals Segment performed well, making steady progress against the annual plan.

　The interim dividend has been set at ¥21 per share (the converted interim dividend per share before the share split would be ¥63 per share, an increase of ¥7 from the previous year’s interim dividend), and the amount allocated for the purchase of treasury stock has been set at ¥5,000 million. In addition, concerning the forecast of our consolidated financial results for the current fiscal year, we have revised upward the figures announced in May 2024 for net sales, operating income, ordinary income, and profit attributable to owners of parent, based on the current business environment and demand forecast.

　The Group provides products and services that meet new needs by responding swiftly to market changes and aims to make a leap forward as a global company through innovative approaches and proactive reforms.

　Today, with moves toward decarbonization and environmental preservation aimed at realizing a sustainable society growing in importance worldwide, companies are expected to contribute to various social issues. The Group will continue to endeavor to create new value with the power of chemistry, and meet the expectations of all of our stakeholders, with the aim of achieving a secure and affluent society.

　We kindly ask all shareholders for your continuing support.
 

November 2024

Koji Sawamura
President & Chief Executive Officer